Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye
- Dr. Jiangbin Ye receives Agilent Solutions Innovation Research Award for cancer research
- Research focuses on connection between cancer metabolism, epigenetic remodeling, and cell dedifferentiation
- Award will support development of therapeutic approaches to target metabolic pathways in cancer cells
- None.
Stanford Medicine researcher recognized for his influential work in cell biology and cancer research
A characteristic of cancer is that malignant cells modulate metabolic pathways to promote cancer progression. Dr. Ye’s research focuses on this particular aspect of cancer metabolism, specifically the connection between the Warburg effect, epigenetic remodeling, and cancer dedifferentiation. The Ye Lab’s investigations into the causes and consequences of the abnormal metabolic phenotypes of cancer cells in response to microenvironmental stresses, such as hypoxia and nutrient deprivation, will aid the prospect that therapeutic approaches might be developed to target these metabolic pathways to improve cancer treatment.
“I am deeply honored to receive the prestigious SIRA from Agilent, a leader in cutting-edge scientific research and technology,” said Dr. Ye. “This award will greatly support our lab's mission to explore the intricate connections between the Warburg effect, epigenetic remodeling, and cell dedifferentiation in cancer cells.”
“With the advanced capabilities of Agilent's cell analysis platforms, including the Seahorse XF Pro, BioTek Cytation 5, and Q-TOF LC/MS, we can strike the complex core of tumorigenesis and unravel the mysteries of cancer progression. Our collaboration with Agilent will undoubtedly accelerate the development of innovative metabolic therapy, ultimately improving cancer treatment and save patients' lives,” added Dr. Ye.
“Agilent is committed to assisting academic researchers in accelerating their area of proficiency, so we are thrilled to present this award to Dr. Ye,” said Nahid Chalyavi, associate vice president of University Relations and External Research at Agilent. “We look forward to following his work as he incorporates some of the most innovative and impactful technologies in his cell biology and cancer research investigations.”
SIRA is a new Agilent University Relations initiative designed to stimulate the most innovative and impactful use of multiple Agilent products to help solve pressing scientific problems. The 2023 award will support advancements in drug discovery and cancer research, enabled using Agilent cell analysis platforms, including the new award-winning Seahorse XF Pro Analyzer optimized for drug discovery research and pharma-oriented workflows, BioTek Cytation 5 Cell Imaging Multimode Reader, and mass spectrometry instruments and workflows that can be used synergistically to improve the understanding of cell biology and cancer.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005334/en/
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com
Source: Agilent Technologies Inc.
